THE PHARMACOKINETIC OF THE MAIN ORAL ANTIBIOTICS IN CHILDREN WITH CYSTIC FIBROSIS ArticleKondakova Y., Kondratyeva E., Zyryanov S., Bondareva I., Sherman V., Melyanovskaya Y.EUROPEAN RESPIRATORY JOURNAL. Том 54. 2019.
AGE PECULIARITIES OF PHARMACOTHERAPY WITH AMOXICILLIN PREPARATIONS IN CHILDREN WITH CYSTIC FIBROSIS ArticleKondratieva E.I., Kondakova Y.A., Zyryanov S.K., Bondareva I.B., Voronkova A.Y., Sherman V.D., Melyanovskaya Y.L., Odinayeva N.D., Dronov I.A.Pediatriya - Zhurnal im G.N. Speranskogo. Том 98. 2019. С. 179-188
MODERN APPROACHES TO IMPROVING THE EFFECTIVENESS OF ANTIBIOTIC THERAPY IN PERINATOLOGY: LOCAL EXPERIENCE ArticleKazanova A.M., Zyryanov S.K., Ivzhits M.A., Kruglov A.N., Kutsaya K.O., Chenkurov M.S.Качественная клиническая практика. 2019. С. 66-74
THE EFFECT OF OPRM1, ABCB1, IL1B, PTGS2, LOC 541472 GENE POLYMORPHISM ON THE VARIABILITY OF CHRONIC PAIN SYNDROME IN PATIENTS WITH PANCREATIC CANCER ArticleBobrova Olga, Schnider Natalya, Zyryanov Sergey, Dmitrenko Diana, Zobova Svetlana, Zukov RuslanКачественная клиническая практика. 2019. С. 53-59
THERAPEUTIC DRUG MONITORING OF LEVETIRACETAM IN NEWBORNS ArticleBondareva I.B., Ivzhits M.A., Zyryanov S.K., Chenkurov M.S.Анналы клинической и экспериментальной неврологии. Том 13. 2019. С. 65-76
PHARMACOLOGY IN SPECIAL POPULATIONS: EXTREME AGE ArticleRomanov B.K., Zyryanov S.K.Качественная клиническая практика. 2019. С. 70-74
PHARMACOKINETICS OF ANTI-BACTERIAL PREPARATIONS IN CYSTIC FIBROSIS IN CHILDREN ArticleKondakova Y.A., Voronkova A.Y., Zyryanov S.K., Bondareva I.B.Сибирское медицинское обозрение. 2019. С. 5-13
PHARMACOECONOMIC EVALUATION OF CEFTOLOSAN + TASOBACTAM IN THE TREATMENT OF COMPLICATED NOSOCOMIAL INTRA-ABDOMINAL INFECTIONS ArticleZyryanov S.K., Dyakov I.N., Khachatryan N.N.Качественная клиническая практика. 2019. С. 55-69
CLINICAL AND ECONOMIC ANALYSIS OF THE AXITINIB AS A SECOND-LINE TARGET THERAPY FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA ArticleZyrianov S.K., Diakov I.N.Medical Technologies. Assessment and Choice. Том 36. 2019. С. 59-68
CLINICAL AND ECONOMIC STUDIES ON PHARMACOTHERAPY OF MALIGNANT NEOPLASMS: THE MODELING APPROACH ArticleTolkushin A.G., Zyryanov S.K., Pogudina N.L., Davydovskaya M.V.FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. Том 11. 2019. С. 48-60
BUDGET IMPACT ANALYSIS OF TERIPARATIDE IN COMPARISON WITH ANTIRE-SORPTIVE DRUGS IN SEVERE OSTEOPOROTIC PATIENTS ArticleDiakov I.N., Belaya Z.E., Zyrianov S.K., Mazurov V.I.Medical Technologies. Assessment and Choice. 2019. С. 71-80
EXTRACELLULAR DNA AND PLASMA NUCLEASE ACTIVITY EFFECT ON THE COURSE OF THE MICROBIAL INFLAMMATORY PROCESS IN THE RESPIRATORY TRACT IN CYSTIC FIBROSIS ArticleKondratieva E.I., Kondakova Yu.A., Kostyuk S.V., Ershova E.V., Zyryanov S.K., Melyanovskaya Yu.L., Voronkova A.Yu., Sherman V.D., Shadrina V.V.Journal of Bioinformatics and Genomics. 2018. 2 с.
CLINICAL CASE OF NON-IMMUNE HYDROPS FETALIS CONGENITAL SYPHILIS ATPRETERMINFANT ArticleShulakova O.A., Karabanov A.M., Zyryanov S.M., Gurevitch K.G.Неонатология: новости, мнения, обучение. 2018. С. 83-87
РЕЗОЛЮЦИЯ СОВЕТА ЭКСПЕРТОВ "ЭМПИРИЧЕСКАЯ АНТИБАКТЕРИАЛЬНАЯ ТЕРАПИЯ ИНФЕКЦИЙ ДЫХАТЕЛЬНЫХ ПУТЕЙ С УЧЕТОМ ФАКТОРОВ РИСКА РЕЗИСТЕНТНОЙ ФЛОРЫ" ArticleКозлов Р.С., Зырянов С.К., Синопальников А.И., Рязанцев С.В., Стырт Е.А.Справочник поликлинического врача. 2018. С. 28-32
ПРОГНОЗНЫЙ ЭКОНОМИЧЕСКИЙ ЭФФЕКТ ПРИМЕНЕНИЯ АЛИРОКУМАБА У ПАЦИЕНТОВ С ГИПЕРХОЛЕСТЕРИНЕМИЕЙ И ВЫСОКИМ СЕРДЕЧНО-СОСУДИСТЫМ РИСКОМ ArticleЗырянов С.К., Дьяков И.Н.Клиническая фармакология и терапия. Том 27. 2018. С. 90-96